Zymeworks Presents Preclinical Data on ZW171 at the Society for Immunotherapy of Cancer (SITC) Conference
We are pleased to present preclinical data on ZW171 in a poster presentation at the annual SITC Conference, taking place November 6-10 in Houston, TX. The poster presentation titled “Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting mesothelin and CD3” (Abstract #: 1062) […]
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Zymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
We’re excited to share further details on our upcoming presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024. Oral Presentation: Title: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and […]
Dr. Raffaele Colombo Honored as a PharmaVoice 100 Winner
Zymeworks is thrilled to announce that Dr. Raffaele Colombo has been honored as a PharmaVoice 100 winner. This annual list recognizes the most inspiring people in the life sciences industry. Dr. Colombo has been instrumental in the advancement of Zymeworks’ wholly-owned pipeline, leveraging his experience and knowledge towards the development of a portfolio of novel […]
Zymeworks Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer Annual Meeting
We are excited to announce a poster presentation highlighting preclinical data for ZW171 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Presentation Details Title: Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting […]
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy as first-line treatment for patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA). Data from […]
